In fact, CELF2 has already been investigated as a therapeutic target in a neuromuscular disease called spinal and bulbar muscular atrophy, and lowering CELF2 levels can improve symptoms in a mouse model of this disorder (Miyazaki et al., 2012). This evidence concerns the gene CELF2 and neuromuscular disease.